Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Resveratrol and Doxorubicin Hydrochloride

Research Papers that Mention the Interaction

However, the combination of resveratrol and doxorubicin exhibited a significant dose-dependent inhibition of CAM angiogenesis in vivo as well as proliferation and tube formation in HUVECs compared to the positive control (±)-thalidomide.
Our results suggest that resveratrol in combination with doxorubicin is a novel strategy in the prevention and treatment of angiogenesis.
Our study reports for the first time the potent ability of resveratrol in combination with doxorubicin to inhibit angiogenesis in vitro and in vivo.
Polish journal of veterinary sciences  •  2020  |  View Paper
RES could reverse DOX resistance in breast neoplasm cells and inhibited DOX‐resistant breast cancer cell propagation and metastasis and facilitated cell apoptosis by modulating PI3K/Akt signaling pathway.
IUBMB life  •  2018  |  View Paper
Further, combined dosages of DOX (5 mg/kg b.wt) and RSVL (10 mg/kg b.wt) inhibited tumor volume with increased life span (139%, p value<0.05) in Ehrlich ascitic carcinoma (EAC) cells bearing mice.
Phytomedicine : international journal of phytotherapy and phytopharmacology  •  2016  |  View Paper
Additionally, RSVL , curcumin, and EEAC had synergistic effects with Dox against MCF-7 breast cancer cells.
RSVL , curcumin, and EEAC have the potential to be clinically applied to prevent cardiac toxicity and HFS and enhance the anticancer efficiency of Dox.
Integrative cancer therapies  •  2015  |  View Paper
Interestingly, the use of resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity as well as to exert a synergistic effect against tumour cells both in vivo and in vitro.
Journal of cellular and molecular medicine  •  2015  |  View Paper
Resveratrol , which has been suggested to attenuate doxorubicin-induced cytotoxicity, significantly blocked induction of AMPKα2 and E2F1 by doxorubicin , leading to protection of these cells.
The Journal of Biological Chemistry  •  2014  |  View Paper
Further in vivo experiments in the xenograft model revealed that treatment with a combination of RSV and Dox significantly inhibited tumor volume by 60%, relative to the control group.
Treatment with a combination of RSV and Dox significantly increased the cellular accumulation of Dox by down-regulating the expression levels of ATP-binding cassette (ABC) transporter genes, MDR1, and MRP1.
Biochimica et biophysica acta  •  2014  |  View Paper
These cardiotoxic effects of DOX were ameliorated by its combination with RES.
Cardiovascular Toxicology  •  2012  |  View Paper
Resveratrol increased the viability of neonatal rat ventricular myocytes that were treated with doxorubicin and reduced doxorubicin-induced bradycardia and QTc interval prolongation in mice.
American journal of obstetrics and gynecology  •  2006  |  View Paper
Acute Rsv potentiated the long-lasting effect of Doxo through the induction of apoptosis and senescence.
However, the cellular and molecular mechanisms underlying the effects of cotreatment with Doxo and Rsv in breast cancer are poorly understood.
In conclusion, acute Rsv potentiated the long-term toxicity of Doxo in breast cancer potentially through the modulation of genes and mechanisms involved in Doxo resistance.
We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1.
Oxidative medicine and cellular longevity  •  2020  |  View Paper
Show More